Artemisinin Combination Therapy Market to Share, Trends during the forecast period 2019 - 2027

The conventional low-priced mainstay drugs for the treatment of malaria, sulphadoxine-pyrimethamine (SP) and chloroquine (CQ), are witnessing a decline in sales, as they are becoming comparatively ineffective. During the last two decades in Asia, the issue has become a major concern. This has resulted in the adoption of artemisinin (derived from the Chinese herb Artemisia annua) in Africa as a standard treatment. It helped in setting a milestone for the artemisinin combination therapy market. The herb has been used to treat fevers and malaria for more than 2000 years. The World Health Organization (WHO) has adopted artemisinin-based combination therapy (ACTs) as the first-line treatment for plasmodium falciparum malaria. As a combination therapy, it has demonstrated superiority to other drugs because of its ability to wipe out parasites and its life cycle stages faster. Its use with cancer transferrin to cure cancer is also adding value to the artemisinin combination therapy market.

Report Overview: https://www.transparencymarketresearch.com/artemisinin-combination-therapy-market.html

Triple ACTs (TACTs) combine with artemisinin and two other existing partner drugs to work effectively as stop-gap therapy for the treatment of multidrug-resistant malaria. It will be used till the arrival of new antimalarial drugs. TACTs are secure, competent, well-accepted, and economical. This artemisinin combination therapy is likely to gain wider acceptance among the target consumers. The barriers in the deployment should be identified and stakeholders should make efforts to overcome them, which will new growth avenues in artemisinin combination therapy market.
Artemisinin Combination Therapy Market Introduction
Artemisinin is a plant derivative isolated from Artemisia annua, or sweet wormwood, which is known to effectively and swiftly reduce the number of plasmodium parasites in the blood of malaria patients. The WHO recommends artemisinin combination therapies (ACTs) as the first line of treatment for uncomplicated plasmodium falciparum malaria and as the second line of treatment for chloroquine-resistant P. vivax malaria.
This therapy combines an artemisinin derivative along with a partner drug, wherein artemisinin aids in reducing the number of parasites and the partner drug eliminates the remaining parasites. Efficacy of the treatment is determined by the drug combined with artemisinin, such as artesunate-mefloquine, dihydroartemisinin-piperaquine, and artemether-lumefantrine.
Falciparum malaria was one of the most common lethal infections which was treated with chloroquine and sulfadoxine-pyrimethamine. However, these drugs are not effective as treatment primarily in the tropical regions owing to the resistance developed against these drugs. According to the Medicines Malaria Venture (MMV), over 445,000 deaths were reported in 2016 due to malaria. The globally rising malaria endemic and the changing climatic conditions would contribute to the trend aiding in the artemisinin combination therapy market growth.
Artemisinin Combination Therapy Market- Competitive Landscape
The strategies adopted by the market players to enhance their market position include indication extension, focus on geographic expansion, and research & development. The national funding allocations, as announced by the Global Fund for 2018-2020, report that the funding available for the promotion of malaria programs is around US$1 billion.
Novartis AG
Novartis AG, established in 1895, is engaged in research, development, manufacturing and marketing of healthcare products across a range of areas, including neuroscience, ophthalmology, immunology, hepatology, respiratory, cardiology, dermatology, and cardio metabolic.
Sanofi
Sanofi, a leading pharmaceutical company is engaged in the manufacturing of prescription pharmaceuticals and vaccines. It is engaged in the development of cardiovascular, metabolic disorder, central nervous system (CNS), oncology, and thrombosis drugs and medicines.
Ipca Laboratories Ltd.
Ipca Laboratories is an Indian pharmaceutical company engaged in the manufacturing of over 350 formulations and 80 APIs for a range of therapeutic indications. According to the company, it is the market leader in India for anti-malarials with a market share of over 34% in 2018.
Artemisinin Combination Therapy Market - Dynamics
Growing malaria endemic
Malaria is a major health concern in endemic countries such as Sudan, wherein over 75% of the population is at the risk of acquiring the disease. Moreover, the widespread presence of chloroquine-resistant strains of P. falciparum in the malaria endemic countries makes artemisinin combination therapy the preferred choice of treatment. This is projected to fuel the growth of the artemisinin combination therapy market.

Request Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=68096

Increase in the procurement of ACT treatment courses
Increase in access to ACTs in the malaria-endemic countries contributes to the rising success in reducing the global malaria burden. According to the WHO, over 2.7 billion ACT treatment courses were procured by global countries between 2010 and 2017. Moreover, over 62% of these procurements were made by the public sector. Strong pipeline for the development of new anti-malarial drugs and launch of newer artemisinin combinations for the treatment of malaria boost to the growth of the global artemisinin combination therapy market.
Challenges related to the availability of raw materials
Challenges pertaining to the availability of intermediate products and raw materials in the production of artemisinin-based combination therapies from agricultural sources are expected to restrain the global artemisinin combination therapy market. Furthermore, volatility in the artemisinin market leading to concerns over supply tightening could create significant risks to patients and market participants.

Request Customization: https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=68096

Artemisinin Combination Therapy Market Segmentation
Global artemisinin combination therapy market can be segmented on the basis of
• Type
• Distribution Channel
Based on the type, the artemisinin combination therapy market is segmented into
• Artesunate-sulfadoxine-pyrimethamine
• Artesunate-amodiaquine
• Artesunate-pyronaridine
• Artemether-lumefantrine
• Artesunate-mefloquine
• Artesunate-atovaquone-proguanil
• Artesunate-chlorproguanil-dapsone
• Dihydroartemisinin-piperaquine
The artemether-lumefantrine segment dominated the artemisinin combination therapy market in 2018, as it was the first ACT to be approved for the treatment of malaria by the WHO for its efficacy, safety, and quality.
Based on the distribution channel, the artemisinin combination therapy market is segmented into
• Public sector providers
• Retail providers
• Others
In the African countries, where retail providers play a major role in the drug distribution, drug shops accounted for a major share. The others segment includes pharmacies, grocery stores, and itinerant hawkers.
The report on artemisinin combination therapy market is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The artemisinin combination therapy market report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The artemisinin combination therapy market report also maps the qualitative impact of various market factors on market segments and geographies.
Regional analysis for Artemisinin Combination Therapy market includes:
• North America
• Europe
• Latin America
• Asia Pacific
• Middle East & Africa (MEA)
Middle East & Africa accounted for major share of the global artemisinin combination therapy market in 2018, owing to malaria endemic in the region. Additionally, the initiatives taken by the government and non-government organizations to spread awareness about ACT treatment for malaria contribute to the growth of the market in the region. Moreover, rise in demand for ACT in malaria endemic countries in Africa such as Uganda and Nigeria boosts the growth of the market in the region.
This intelligence report by TMR is the outcome of intense study and rigorous assessment of various dynamics shaping the growth of the market. TMR nurtures a close-knit team of analysts, strategists, and industry experts who offer clients tools, methodologies, and frameworks to make smarter decisions. Our objective, insights, and actionable analytics provide CXOs and executives to advance their mission-critical priorities with confidence.
The scrutiny of the various forces impacting the dynamics of the market, and key and associated industries, guides enterprises in understanding various consumer propositions. Our clients leverage these insights and perspectives to enhance customer experience in the fast-paced business environment.
All our insights and perspectives are broadly based on 4 Pillars or Stages: ASBC-S, which offer an elaborate and customizable framework for the success of an organization. The essence and the roles of these in organizational successes are highlighted below:

Request for covid19 Impact Analysis: https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=68096

• Agenda for CXOs: TMR, through the study, sets the tone for agendas that are pertinent to CEOs, CFOs, CIOs, and other CXO executives of businesses operating in the market. The perspectives help our clients to bridge the gap between agenda and action plan. TMR strives to offer guidance to CXOs to undertake mission-critical activities empowered by various business analysis tools, and boost the performance of the organizations. The perspectives guide you to decide on your own marketing mix that align well with the policies, visions, and mission.
• Strategic Frameworks: The study offers how organizations are setting both short-term and long-term strategic plans. Our team of experts collaborate and communicate with you to understand these to make your organizations sustainable and resilient during tough times. The insights help them decide sustainable competitive advantage for each business units.
• Benchmarking for Deciding Target Markets and Brand Positioning: The assessments in the study provides a scrutiny of marketing channels and marketing mix. Our various teams work synergistically with you to help identify your actual and potential direct, indirect, and budget competition areas. Additionally, the study helps you decide most effective budgets for various processes and promotional activities. Furthermore, the study guides you to set benchmarks for integrating people and processes with the 4Ps of marketing. Eventually, this will empower you to find out unique propositioning strategies and niches.
• Business Composability for Sustainability (C-S): Constant strategy planning for sustainability characterizing our C-S framework in the report has become more relevant than before in the face of disruptions caused by pandemics, recessions, boom and bust cycles, and changing geopolitical scenario. The TMR study offers a high level of customization to help you achieve business composability. Composable enterprises are increasingly gaining the attention of CXOs in order to help them combat market volatility. Our analysts and industry experts help you wade through such uncertainties and guide you to become a smart sustainable business in entirety.

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/home-healthcare-market-to-expand-at-10-5-during-forecast-period-states-tmr-study-301477668.html

https://www.prnewswire.com/news-releases/telehealth-market-to-expand-at-cagr-of-7-during-forecast-period-observes-tmr-study-301480663.html

Contact
Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/

About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

This release was published on openPR.